MOTS-c and SS-31: How to Choose the Right One
$39.99 USD
MOTS-c and SS-31: How to Choose the Right One
$39.99 USD
Most researchers treating an energy problem are solving for the wrong failure point. MOTS-c and SS-31 both carry a mitochondrial label. That label is where the decision usually goes wrong.
This guide is built as a diagnostic framework, not a compound overview. The goal is to separate two failure modes that produce identical symptoms from the outside — one is a signaling problem, one is a structural problem — and show you how to identify which one is actually present before choosing a compound. The wrong first move does not just produce a weak result. It often produces a misleading one that sends the next decision in the wrong direction.
What this guide covers
Why the Label Fails
Both compounds fall under mitochondrial support. That category is accurate and useless at the same time. This guide explains why the label does not tell you which problem you have.
The Phase Framework
Energy problems in a peptide protocol follow a progression across three phases. The phase determines which tool is rational. Applying a Phase 3 tool in Phase 2 — or the reverse — produces a result that looks like compound failure when the real issue was sequence failure.
The Foundation Gate
Four inputs that have to be stable before any compound decision is relevant. Sleep, stimulant load, chronic stress, and training stimulus. If any of these fail the check, that input is the first intervention — not a compound addition.
The Three Patterns
Metabolic flexibility failure, mitochondrial membrane damage, and the stimulant trap. Each one can look like the others from the outside. Each one has a different solution. This guide shows you how to tell them apart using symptom texture rather than symptom presence.
MOTS-c — What It Actually Does
A signaling compound. It activates AMPK, the cellular energy sensor, and tells the body to use available fuel more efficiently. It produces a felt effect. It is a Phase 2 tool. Adding it in Phase 3 accelerates the load on a system that cannot support it.
SS-31 — What It Actually Does
A structural stabilizer. It targets the inner mitochondrial membrane and reduces energy leakage in the conversion process. It does not produce a felt effect. The correct output is the gradual disappearance of a problem, not the arrival of a new sensation.
The Stacking Mistake
Running both compounds before confirming which pattern is present produces an unreadable experiment. This guide covers the four outcomes that result and why three of the four are consistently misread.
Decision Tree and Dose Reference
A seven-step sequence that moves from GLP-1 audit through foundation gate to pattern identification to compound selection. Includes reference ranges, assessment windows, and what to watch for at each stage.
Who this is for
Researchers who have tried MOTS-c or SS-31 and concluded the compound did not work — without having confirmed which failure pattern was present before starting.
Researchers who are experiencing flat energy or stalled fat loss in a GLP-1 protocol and are trying to determine whether the problem is a signaling issue, a structural issue, or something else entirely.
Researchers who are considering running both compounds simultaneously and want to understand why that decision is usually a mistake and when it is actually warranted.
Anyone who wants to understand why the same compound can produce a felt improvement in one context and make things measurably worse in another.
How these two compounds differ at the mechanism level
The distinction is not about dose or severity. It is about which part of the energy system is failing.
| Compound | What it does | Pattern it fits |
|---|---|---|
| MOTS-c | Activates AMPK — the cellular energy sensor. Improves how efficiently the body uses available fuel. Demand-side. Raises the output signal. | Phase 2 only. Energy crashes after meals and recovers with food. Metabolic flexibility failure. |
| SS-31 | Stabilizes cardiolipin in the inner mitochondrial membrane. Reduces energy leakage in the conversion process. Supply-side. Restores structural efficiency. | Phase 3 only. Energy flat regardless of food timing. Recovery extended to two or three days. |
| Either / Or | Not a stack decision. A diagnosis decision. Running both before identifying the failure pattern adds cost without leverage and produces an unreadable result. | Overlap pattern exists but requires staged confirmation — Phase 2 addressed first, Phase 3 markers assessed after. |
| Neither | If the GLP-1 dose is too high, or the stimulant load is creating the fatigue, or the foundation gate is not cleared — no compound corrects an environment that is actively working against it. | Pattern 3 — stimulant trap. Or foundation gate failure. The intervention is lifestyle correction, not compound addition. |
Diagnostic flowchart — preview
1
Has energy declined since a recent GLP-1 dose escalation, and has a dose reduction or timing adjustment been tested?
2
Is energy functional with stimulants and genuinely non-functional without them — not lower, non-functional?
3
Does energy follow a meal-dependent arc — reasonable after eating, crashing in the fasted window — or is it flat regardless of food timing?
4
Are sleep, stimulant load, chronic stress, and training stimulus all stable enough that none of them is the primary limiting variable?
Result A — Phase 2 Pattern
Meal-dependent energy arc confirmed. Foundation gate cleared. GLP-1 variable ruled out. NAD+ first, then MOTS-c. Assessment window is four to six weeks. Watch the fasted window, not day one sensation.
Result B — Phase 3 Pattern
Flat energy regardless of food timing. Recovery extended. Oxidative load history present. NAD+ first, then SS-31. Expect no acute effect. The signal is recovery capacity at three to six weeks.
Result C — Stimulant Trap
No compound is appropriate yet. Neither MOTS-c nor SS-31 can outpace a damage source that is still active. Reduce stimulant load alongside sleep correction before any compound decision is relevant.
Result D — GLP-1 Dose Problem
The energy pattern may resolve with a dose adjustment or timing change before any compound is added. This audit costs nothing and takes two weeks. It is always the first check.
If the framework is not enough
This guide identifies which failure pattern is present and gives you the diagnostic framework to act on it. There is a category of stall it cannot reach — where the pattern appeared clear but a second variable was running underneath the whole time, or where both Phase 2 and Phase 3 markers are present simultaneously and the sequencing question becomes more complex than a general framework can resolve. That is what the Protocol Audit is designed for.
For educational and research purposes only | Not medical advice | Not for human use guidance | Project Theo
Styled With
